Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | GPR3 | P46089 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.31 |
| ▸ | F12 | P00748 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL700437 | 0.76 | GPR3 (0.41) | SMN1; SMN2GPR3ATMGAAALDH1A1 | |
| SCHEMBL7289573 | 0.76 | — | — | |
| SCHEMBL7035643 | 0.74 | GPR3 (0.39) | SMN1; SMN2GPR3ATMALDH1A1MAPT | |
| SCHEMBL9237914 | 0.74 | — | — | |
| SCHEMBL7838631 | 0.71 | GPR3 (0.37) | SMN1; SMN2GPR3ALDH1A1MAPTCA12 | |
| SCHEMBL2704346 | 0.71 | KMT2A (0.40) | SMN1; SMN2GPR3GAAALDH1A1KMT2A | |
| SCHEMBL3088034 | 0.67 | P2RX4 (0.50) | SMN1; SMN2GAAALDH1A1MAPTKMT2A | |
| SCHEMBL4014784 | 0.67 | ALDH1A1 (0.35) | SMN1; SMN2GPR3ATMGAAALDH1A1 | |
| SCHEMBL4083502 | 0.67 | SLC6A2 (0.33) | SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL15062740 | 0.66 | TNF (0.50) | SMN1; SMN2ALDH1A1MAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170079954-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2017-03-23 | — | — | US | claimed |
| US-9540351-B2 | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors | AXIKIN PHARMACEUTICALS, INC. (US) | 2017-01-10 | — | — | US | claimed |
| EP-3046918-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | Axikin Pharmaceuticals, Inc. (US) | 2016-07-27 | — | — | EP | claimed |
| US-9382237-B2 | 3,5-diaminopyrazole kinase inhibitors | AXIKIN PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | claimed |
| US-9365556-B2 | 3,5-diaminopyrazole kinase inhibitors | AXIKIN PHARMACEUTICALS, INC. (US) | 2016-06-14 | — | — | US | claimed |
| US-9346792-B2 | 3,5-diaminopyrazole kinase inhibitors | AXIKIN PHARMACEUTICALS, INC. (US) | 2016-05-24 | — | — | US | claimed |
| US-20150105389-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2015-04-16 | — | — | US | claimed |
| EP-2852586-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | Axikin Pharmaceuticals, Inc. (US) | 2015-04-01 | — | — | EP | claimed |
| WO-2015042111-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. (US) | 2015-03-26 | — | — | WO | claimed |
| US-20150080397-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2015-03-19 | — | — | US | claimed |
| US-20150080398-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2015-03-19 | — | — | US | claimed |
| EP-2834232-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | Axikin Pharmaceuticals, Inc. (US) | 2015-02-11 | — | — | EP | claimed |
| US-8916555-B2 | 3,5-diaminopyrazole kinase inhibitors | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-12-23 | — | — | US | claimed |
| US-20130303492-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2013-11-14 | — | — | US | claimed |
| US-20130274227-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-10-17 | — | — | US | claimed |
| WO-2013138617-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | WO | claimed |
| WO-2013138613-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | WO | claimed |
| US-20170079954-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2017-03-23 | — | — | US | disclosed |
| EP-1243580-A1 | HETEROCYCLIC IMINO COMPOUNDS AND FUNGICIDES AND INSECTICIDES FOR AGRICULTURAL AND HORTICULTURAL USE | Nissan Chemical Industries, Ltd. (JP) | 2002-09-25 | — | — | EP | disclosed |
| US-6268514-B1 | TREATING INDUSTRIAL MATERIALS WITH NITROETHANE COMPOUND FOR PROTECTING AGAINST ATTACK AND DESTRUCTION BY MICROORGANISMS | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274227-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | MAP3K13, MAP3K3, MAP3K1 | SMN1; SMN2 3864/4885GPR3 849/4885ATM 324/4885 |
| US-20170079954-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | GRK3, DMPK, PRKAG3 | SMN1; SMN2 3274/4885GPR3 630/4885ATM 410/4885 |
| US-20150080398-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | MAP3K13, MAP3K3, MAP3K1 | SMN1; SMN2 3864/4885GPR3 849/4885ATM 324/4885 |
| US-20150105389-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | MAP3K13, MAP3K3, MAP3K1 | SMN1; SMN2 3864/4885GPR3 849/4885ATM 324/4885 |
| US-20150080397-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | GRK3, DMPK, PRKAG3 | SMN1; SMN2 3274/4885GPR3 630/4885ATM 410/4885 |
| US-20130303492-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | MAP3K13, MAP3K3, MAP3K1 | SMN1; SMN2 3864/4885GPR3 849/4885ATM 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.